



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 37/02, C07K 7/10		A1	(11) International Publication Number: WO 99/40928
			(43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/US99/02603		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 5 February 1999 (05.02.99)			
(30) Priority Data: 60/074,746 13 February 1998 (13.02.98) US			
(71) Applicant (for all designated States except US): AMYLIN PHARMACEUTICALS, INC. [US/US]; 9873 Towne Centre Drive, San Diego, CA 92121 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BEELEY, Nigel, R., A. [US/US]; 227 Loma Corta Drive, Solana Beach, CA 92075 (US); PRICKETT, Kathryn, S. [US/US]; 7612 Trailbrush Terrace, San Diego, CA 92126 (US); BEAUMONT, Kevin [US/US]; 10872 Pinot Noir Circle, San Diego, CA 92131 (US).			
(74) Agents: MUNSON, Peter, R. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).		Published With international search report.	
(54) Title: NOVEL MIXED AMYLIN ACTIVITY COMPOUNDS			
(57) Abstract <p>Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndrome X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.</p>			

09622404-0722960